絞り込み

16533

広告

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.

著者 Tanabe H , Yoshino K , Ando K , Nomura Y , Ohta K , Satoh K , Ichiishi E , Ishizuka A , Otake T , Kohgo Y , Fujiya M , Okumura T
Ann Clin Microbiol Antimicrob.2018 Jun 28 ; 17(1):29.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (49view , 0users)

Full Text Sources

All Helicobacter pylori-infected patients are recommended for eradication with an appropriate regimen in each geographic area. The choice of the therapy is somewhat dependent on the antimicrobial susceptibility. The rate of clarithromycin resistance has been increasing and is associated with failure; thus, susceptibility testing is recommended before triple therapy with clarithromycin. However, antimicrobial susceptibility testing is not yet clinically available and an alternative newly developed acid inhibitor vonoprazan is used for triple therapy in Japan. The aim of this study was to determine whether vonoprazan-based triple therapy is plausible treatment in H. pylori eradication.
PMID: 29950163 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード